EUVIMEDObjevte EUVIMED
Open access

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer

Atish Mohanty iD, Arin Nam, Saumya Srivastava, Jeff Jones iD, Brett Lomenick iD, Sharad S Singhal, Linlin Guo, Hyejin Cho iD, Aimin Li, Amita Behal, Tamara Mirzapoiazova, Erminia Massarelli and 23 more

Science Advances · 2023-10-13 · 9 (41)

DOI: 10.1126/sciadv.ade3816 ↗

At a glance

Journal article in Science Advances, published on 2023-10-13. Written by Atish Mohanty and 34 co-authors. Institution: Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm. Cited 85 times so far (Crossref); 68 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NIGMS NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Inherent or acquired resistance to sotorasib poses a substantialt challenge for NSCLC treatment. Here, we demonstrate that acquired resistance to sotorasib in isogenic cells correlated with increased expression of integrin β4 (ITGB4), a component of the focal adhesion complex. Silencing ITGB4 in tolerant cells improved sotorasib sensitivity, while overexpressing ITGB4 enhanced tolerance to sotorasib by supporting AKT-mTOR bypass signaling. Chronic treatment with sotorasib induced WNT expression and activated the WNT/β-catenin signaling pathway. Thus, silencing both ITGB4 and β-catenin significantly improved sotorasib sensitivity in tolerant, acquired, and inherently resistant cells. In addition, the proteasome inhibitor carfilzomib (CFZ) exhibited synergism with sotorasib by down-regulating ITGB4 and β-catenin expression. Furthermore, adagrasib phenocopies the combination effect of sotorasib and CFZ by suppressing KRAS activity and inhibiting cell cycle progression in inherently resistant cells. Overall, our findings unveil previously unrecognized nongenetic mechanisms underlying resistance to sotorasib and propose a promising treatment strategy to overcome resistance.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmHumansAntiviral Agentsbeta CateninMutationProto-Oncogene Proteins p21(ras)

Substances

Antiviral Agentsbeta CateninKRAS protein, humanProto-Oncogene Proteins p21(ras)

Authors and institutions

  • Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Proteome Exploration Laboratory, California Institute of Technology, Pasadena, CA 91125, USA.
  • Integrative Genomics Core, Beckman Research Institute, City of Hope, Monrovia, CA 91016, USA.
  • Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010,USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

ORCID profiles: Atish Mohanty, Jeff Jones, Brett Lomenick, Hyejin Cho, Tonya Walser, Stanley Hamilton, Isa Mambetsariev, Martin Sattler, Mohd W Nasser, Maneesh Jain, Surinder K Batra, Raffaella Soldi, Marwan Fakih, Saswat Kumar Mohanty, Avijit Mainan, Xiwei Wu, Tsui-Fen Chou, Susmita Roy, Ravi Salgia

Funding

  • NCI NIH HHS
  • NIGMS NIH HHS

Cite

APA

Mohanty, A., Nam, A., Srivastava, S., Jones, J., Lomenick, B., Singhal, S. S., Guo, L., Cho, H., Li, A., Behal, A., Mirzapoiazova, T., Massarelli, E., Koczywas, M., Arvanitis, L. D., Walser, T., Villaflor, V., Hamilton, S., Mambetsariev, I., Sattler, M., …, & Salgia, R. (2023). Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Science Advances, 9(41). https://doi.org/10.1126/sciadv.ade3816

Vancouver

Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, et al. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Science Advances. 2023;9(41). doi:10.1126/sciadv.ade3816

BibTeX
@article{Mohanty2023,
  author = {Mohanty, Atish and Nam, Arin and Srivastava, Saumya and Jones, Jeff and Lomenick, Brett and Singhal, Sharad S and Guo, Linlin and Cho, Hyejin and Li, Aimin and Behal, Amita and Mirzapoiazova, Tamara and Massarelli, Erminia and Koczywas, Marianna and Arvanitis, Leonidas D and Walser, Tonya and Villaflor, Victoria and Hamilton, Stanley and Mambetsariev, Isa and Sattler, Martin and Nasser, Mohd W and Jain, Maneesh and Batra, Surinder K and Soldi, Raffaella and Sharma, Sunil and Fakih, Marwan and Mohanty, Saswat Kumar and Mainan, Avijit and Wu, Xiwei and Chen, Yihong and He, Yanan and Chou, Tsui-Fen and Roy, Susmita and Orban, John and Kulkarni, Prakash and Salgia, Ravi},
  title = {Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {41},
  doi = {10.1126/sciadv.ade3816}
}
Start for free →